10-K: PepGen Inc. 10-K Filing: Advancing Oligonucleotide Therapies for Neuromuscular and Neurologic Diseases

PepGen Inc.'s 10-K filing details the company's progress in developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, highlighting clinical trial advancements and financial status.

Summary

• PepGen Inc. is a clinical-stage biotech company focused on oligonucleotide therapeutics for neuromuscular and neurologic diseases.
• The company's Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides to improve drug uptake and activity.
• PepGen's pipeline includes two clinical-stage programs: PGN-EDO51 for Duchenne muscular dystrophy (DMD) and PGN-EDODM1 for myotonic dystrophy type 1 (DM1).
• PGN-EDO51 showed high levels of exon skipping in a Phase 1 trial, leading to two Phase 2 studies: CONNECT1 (open-label) and CONNECT2 (placebo-controlled).
• PGN-EDODM1 received FDA Fast Track designation and is in a Phase 1 trial (FREEDOM), with a Phase 2 trial (FREEDOM2-DM1) planned.
• The company is also developing preclinical programs for additional DMD sub-populations, including exon 53, 45 and 44 skipping.
• PepGen's EDO platform aims for enhanced delivery to skeletal, cardiac, and smooth muscle, with improved activity and tolerability.
• The company has a modular, scalable, and cost-efficient manufacturing process that does not require cell-based processes.
• PepGen faces competition from other oligonucleotide and gene therapy companies, including Sarepta, Dyne, and Avidity.
• The company reported a net loss of $78.6 million for 2023 and $69.1 million for 2022.
• As of December 31, 2023, PepGen had $110.4 million in cash, cash equivalents, and marketable securities.
• PepGen believes its current financial resources will fund operations into 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong preclinical and early clinical data, but also acknowledges the significant risks and challenges inherent in drug development and the need for substantial future funding. The company's technology and early results are promising, but the path to commercialization is long and uncertain.

Positives

• The EDO platform has shown enhanced delivery to various muscle tissues, including cardiac muscle.
• PGN-EDO51 has demonstrated high levels of exon skipping in humans and NHPs.
• PGN-EDO51 was generally well-tolerated in a Phase 1 clinical study.
• PGN-EDODM1 has shown robust pharmacological activity in preclinical models.
• The company has a scalable and cost-efficient manufacturing process.
• The company has a modular manufacturing process that is highly scalable and easily characterizable.
• The company has a strong scientific advisory board with expertise in neuromuscular and neurologic diseases.

Negatives

• PepGen has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• The company will need to raise substantial additional funding to continue its operations.
• The company is early in its development efforts and it will be years before it commercializes a product candidate, if ever.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for manufacturing, research, and testing, which may not perform satisfactorily.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The price of the company's common stock is volatile and fluctuates substantially.

Risks

• The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• The company will need to raise substantial additional funding, and if unable to do so, may have to delay or discontinue product development programs.
• The company is early in its development efforts, and it will be years before it commercializes a product candidate, if ever.
• Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for manufacturing, research, and testing, which may not perform satisfactorily.
• The company faces significant competition, and competitors may develop more effective or safer products.
• The company may not be able to obtain and maintain patent protection for its technology.
• The company may encounter difficulties in managing its growth and retaining key personnel.
• The price of the company's common stock is volatile and fluctuates substantially.
• The company's product candidates may cause undesirable side effects or have other unexpected adverse properties.
• The company may experience delays in the commencement, enrollment, or completion of clinical trials.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to achieve market acceptance of its product candidates, even if approved.
• The company may be subject to product liability lawsuits.
• The company may be subject to data privacy and security breaches.
• The company may be subject to healthcare laws and regulations that could expose it to criminal sanctions and civil penalties.

Future Outlook

PepGen believes its current financial resources will fund operations into 2026 and expects to continue to incur significant expenses as it advances its clinical programs and expands its pipeline.

Management Comments

• The company believes that its EDO platform has the potential to deliver therapeutic agents to the nucleus of target cells.
• The company believes that repeat dosing of PGN-EDO51 may lead to therapeutically relevant accumulation of DMD exon 51-skipped transcript and an associated increase in dystrophin protein.
• The company believes that PGN-EDODM1 has the potential to selectively and directly address the underlying genetic defect central to DM1.
• The company believes that its EDO technology has the potential to facilitate the delivery of multiple classes of nucleic acid payloads.

Industry Context

PepGen is operating in a competitive landscape with other companies developing oligonucleotide and gene therapies for neuromuscular and neurologic diseases. The company's EDO platform and focus on targeted delivery differentiate it from some competitors.

Comparison to Industry Standards

• PepGen's PGN-EDO51 has shown higher levels of exon skipping in humans compared to publicly available data for other DMD exon 51-skipping approaches, including Sarepta's eteplirsen and vesleteplirsen (SRP-5051).
• In NHPs, PGN-EDO51 achieved over 70% exon 51 skipping in skeletal muscle, including the diaphragm, which is believed to be the highest level reported for any approved therapeutic or known development candidate.
• PepGen's PGN-EDO23, a murine analogue of PGN-EDO51, resulted in higher levels of dystrophin production in mdx mice compared to murine analogues of other clinical-stage DMD therapeutic candidates.
• PepGen's EDO technology has shown enhanced delivery of PMO to additional tissues, including the heart, compared to the R6G conjugate, which is structurally equivalent to Sarepta's SRP-5051.
• PepGen's PGN-EDO53 demonstrated single-dose exon skipping levels almost seven times higher than a comparator PPMO in NHPs, suggesting a potential advantage over other exon 53-skipping approaches like Sarepta's VYONDYS 53 and NS Pharma's VILTEPSO.

Related Party Transactions

• The company has a license agreement with Oxford University Innovation Limited and the Medical Research Council, which are related parties.
• The company had a services agreement with Carnot Pharma, LLC, an entity controlled by RA Capital Management, L.P., which is a related party.

Stakeholder Impact

• Shareholders face risks associated with the volatility of the company's stock price and the potential for dilution.
• Employees may benefit from the company's growth and success, but also face risks associated with the company's financial stability.
• Patients with DMD and DM1 may benefit from the company's development of new therapies.
• Suppliers and creditors face risks associated with the company's financial stability and ability to meet its obligations.

Next Steps

• The company will continue to advance PGN-EDO51 through Phase 2 clinical trials (CONNECT1 and CONNECT2).
• The company will continue to advance PGN-EDODM1 through Phase 1 (FREEDOM) and Phase 2 (FREEDOM2-DM1) clinical trials.
• The company plans to advance PGN-EDO53 into IND/CTA-enabling preclinical studies in 2024.
• The company will continue to expand its pipeline of oligonucleotide therapeutic candidates.
• The company will continue to evaluate new cargos and peptide technologies for its EDO platform.

Key Dates

Keywords

oligonucleotide therapeutics, neuromuscular diseases, neurologic diseases, Duchenne muscular dystrophy, myotonic dystrophy type 1, exon skipping, cell-penetrating peptides, clinical trials, drug delivery, biotechnology